Head Of Eisai Sees MGI Buy As Road To Continued Growth
This article was originally published in PharmAsia News
Eisai's president says the Japanese firm's purchase of MGI Pharma, a U.S. biotechnology company, was done to give Eisai a way to continue growing as patents for its moneymaking drugs expire over the next few years. Haruo Naito said MGI was attractive because of its pipeline of promising cancer drugs, with some of its candidates complementary with Eisai's own. He acknowledged Eisai depends heavily on its Alzheimer's drug Aricept (donepezil) and its heartburn and acid reflux medication Pariet/Aciphex (rabeprazole), with Aricept set to lose U.S. patent protection in 2010. (Click here for more - a subscription may be required
You may also be interested in...
No device-related warning letters were released by the US FDA the week of 24 November.
Mooted some time ago, the Medicare Part D Drug Rebate Rule and the Medicare Part B Most-Favored-Nation Model have now been finalized by US President Donald Trump. But US off-patent body the Association for Accessible Medicines feels “further action is necessary.”
Lannett will launch a further seven products in fiscal 2021, after launching four products recently in the first quarter of FY21. The company also plans to pay off its Term Loan ‘A’ in full, by the end of November 2020.